Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Genetics Institute, Transkaryotic deal

TKT licensed the rights to GENIZ's Factor VIII gene for the development of gene therapy

Read the full 156 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE